

Achtergrondinformatie

(10)(2e) (uit overzicht (10)(2e))

- The (10)(2e) together with the (10)(2e) (10)(2e) is currently examining the possibility to support companies with promising vaccine developments and production sites in (10)(2e) with financial contributions. The aim is to further clinical trial performance and widen production capacities so that sufficient production capacities can be built up in parallel to the scientific development of a vaccine. These investments are complementary to the funding of international initiatives (GAVI, CEPI).
- Since COVID-19 is a potentially life-threatening disease, we believe that every individual in our population should have the opportunity to get vaccinated when there is a safe and effective vaccine available. When there are initially limited amounts of vaccine doses available, STIKO will define priority groups who should be vaccinated first, then followed by the remaining populations. The exact strategy and timelines will depend (among others) on the amounts of vaccine doses that will become available over time (e.g. by week). The total number of doses needed for our country is therefore roughly the number of people living in Germany, multiplied by the number of doses required to obtain full protection (for many vaccine products this is probably 2 vaccine doses per person).